NATROBA Drug Patent Profile

When do Natroba patents expire, and what generic alternatives are available?

Natroba is a drug marketed by Cipher and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the spinosad profile page.

DrugPatentWatch^® Generic Entry Outlook for Natroba

Natroba was eligible for patent challenges on January 18, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 25, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for NATROBA

US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	5,673
Drug Prices:	Drug price information for NATROBA
What excipients (inactive ingredients) are in NATROBA?	NATROBA excipients list
DailyMed Link:	NATROBA at DailyMed

See drug prices for NATROBA

See drug sales revenues for NATROBA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NATROBA

Constraining patent/regulatory exclusivity:

9,895,388

NDA:

022408

Dosage:

SUSPENSION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NATROBA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MicroConstants, Inc.	Phase 4
Concentrics Research	Phase 4
Medpace, Inc.	Phase 4

See all NATROBA clinical trials

Pharmacology for NATROBA

Drug Class

Pediculicide

US Patents and Regulatory Information for NATROBA

NATROBA is protected by one US patents.

This potential generic entry date is based on patent 9,895,388.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011		RX	Yes	Yes	9,895,388

Expired US Patents for NATROBA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	5,496,931
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	6,342,482
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	7,030,095
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	6,063,771

EU/EMA Drug Approvals for NATROBA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Elanco GmbH	Comfortis	spinosad	EMEA/V/C/002233Treatment and prevention of flea infestations (Ctenocephalides felis).The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).	Withdrawn	no	no	no	2011-02-11

International Patents for NATROBA

See the table below for patents covering NATROBA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	116325
Australia	4689189
Australia	624458
Australia	631693
Australia	6641490
Bulgaria	60520
Brazil	1100144

Supplementary Protection Certificates for NATROBA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0375316	350009	Netherlands
0375316	SPC/GB02/028	United Kingdom		PRODUCT NAME: SPINOSAD; REGISTERED: CH W 6020 20010313; UK 0714 20020227
0375316	06C0047	France		PRODUCT NAME: SPINOSAD; REGISTRATION NO/DATE IN FRANCE: 2060098 DU 20060628; REGISTRATION NO/DATE AT EEC: 9275/B DU 20011023
0375316	C350009	Netherlands		PRODUCT NAME: SPINOSAD, DESGEWENST IN DE VORM VAN EEN ZOUT; NATL. REGISTRATION NO/DATE: 12363 N 20020913; FIRST REGISTRATION: SE 4511 20020204

Last updated: July 23, 2026

NATROBA (spinosad topical suspension) Market Dynamics and Financial Trajectory: Revenue drivers, exclusivity cliffs, payer and competitive pressure

Natroba (spinosad topical suspension 0.9%) is a dermatology parasiticide sold in the US for head lice. Its financial trajectory is driven by: (1) the size and migration of the treated head-lice population, (2) formulary dynamics versus alternative OTC and prescription pediculicides, (3) channel inventory cycles typical of seasonal lice activity, and (4) the patent and exclusivity timeline that governs competitive entry risk. The product’s long-term ceiling is set by biologic and infectious diseases are not relevant here; the key risks are generic or authorized-competitor erosion and substitution within lice treatment classes.

Attribution note: No license, Orange Book status, FDA labeling revenue disclosures, or company financial statements were provided in the request, and no market-size or net sales dataset is included. Without those inputs, an accurate numeric financial trajectory (annual revenue, CAGR, gross-to-net trend, payer mix) and a definitive exclusivity/competition timeline cannot be produced.

What is Natroba’s market position in head lice treatment and how does it compete on formulary?

Natroba sits in the US head-lice treatment market where prescriber behavior depends on:

• Clinical preference for faster kill and lower re-treatment relative to older prescription pediculicides.
• Safety and tolerability perceptions versus product-specific adverse event profiles.
• Access driven by prior authorization, step therapy, and net price after rebates.
• Convenience and regimen adherence (single or shorter treatment regimens reduce friction).

Which alternative treatments pressure Natroba and how does substitution work?

Key competitive substitutes typically include:

• OTC lice control products (permethrin-based and other OTC actives) that can shift demand away from prescription channels.
• Prescription pediculicides in the same therapeutic class that compete for remaining formulary share.
• Non-prescription mechanical removal approaches that can reduce repeat physician visits.

How do payers and PBMs shape Natroba uptake?

For a product like Natroba, payer leverage usually manifests through:

• Formulary tier placement and copay design for beneficiaries who fill at retail.
• Prior authorization rules keyed to diagnosis confirmation and prior therapy documentation.
• Quantity limits and re-treatment rules tied to labeling intervals.

What are the demand drivers behind Natroba’s sales and how do seasonal patterns affect revenue?

Head lice prevalence in the US tends to concentrate in school-age and community transmission settings, which creates:

• Seasonality in prescription volumes aligned to school terms and outbreaks.
• Spike-then-normalize cycles that increase inventory management risk for manufacturers and wholesalers.
• Short customer lifetime dynamics at the patient level because episodes are acute, not chronic.

How do repeat episodes change lifetime value versus single-episode sales?

While each treatment course is finite, repeat infestations can occur within households. That means revenue is partly determined by:

• Household contagion management and adherence to combing and environmental steps.
• Re-infestation rates that can vary by community and socioeconomic factors.

How do channel inventory and wholesaler ordering impact reported financials?

In dermatology parasiticides, reported sales can show:

• Temporary divergence between sell-in and sell-through due to stocking.
• Post-inventory normalization effects that compress growth even when underlying prescriptions remain steady.

When does Natroba lose exclusivity and what generic entry risks exist?

A precise answer requires Orange Book listing(s) for spinosad topical suspension 0.9%, including each listed patent’s expiration, exclusivity determinations, and whether there are composition, method-of-use, or formulation patents still in-force. The question also requires known Paragraph IV filings and litigation records, which were not provided.

What patent estate categories typically govern erosion for topical pediculicides?

For topical suspensions, the risk profile usually splits into:

• Composition-of-matter for spinosad and/or its key chemical forms.
• Formulation patents covering concentration, suspension stability, surfactants, viscosity targets, and particle-size distributions.
• Manufacturing method patents that can delay generic product approval or commercialization.
• Method-of-use or regimen patents (less common for older lice products, but present in some estates).

What is the Orange Book status of Natroba and how many patents cover it?

No Orange Book dataset was included, so the number of listed patents, their expiration dates, and claim scope cannot be stated accurately.

Which patent types would you expect to be listed for a topical suspension?

Common listing groupings for topical generics include:

• Drug substance or composition patents
• Drug product/formulation patents
• Certain manufacturing process patents

What does Orange Book listing structure imply for generic approval timing?

Where formulation and process patents are listed, generic entry is often delayed even if composition-of-matter has expired, because FDA approval can still be limited by remaining “listed” patents and related litigation.

What patent litigation and settlements could affect Natroba’s competitive landscape?

A complete, accurate litigation and settlement map requires docket-level details tied to any Paragraph IV notices, district courts, and any final judgments or settlement-triggered launch dates. None were provided.

How does Natroba litigation history usually translate into launch pacing?

If challenges exist, typical outcomes include:

• Launch stays until a court decision or settlement date.
• Carve-outs that allow launch only for certain strengths or dosage forms.
• Settlement agreements that trade delayed entry for a non-adjudicative payment.

How strong is the patent estate for Natroba and what is the likely impact on pricing power?

Patent strength analysis depends on:

• Claim coverage (scope breadth)
• Remaining term
• Litigation posture and outcomes
• Existence of enforceable formulation or method-of-use claims

Without the listed patents and their legal status, a strength rating cannot be produced.

How pricing power usually evolves as head lice competition increases

As competition increases, Natroba pricing tends to face:

• Higher rebate pressure to maintain formulary placement.
• Channel margin compression if wholesalers shift to lower-cost SKUs.
• Increased demand for patient assistance, which can change net-to-gross dynamics.

How does Natroba’s financial trajectory compare with competing pediculicides?

A numeric comparative analysis requires net sales for Natroba and peer products, and usually includes:

• US prescription sales
• WAC vs net pricing
• Share by channel (retail vs specialty)
• Gross-to-net reductions over time

Those figures were not provided, so a data-backed comparison cannot be completed.

What metrics matter most for a fair comparison

For topical pediculicides, the most actionable comparisons typically include:

• Net sales trend by year
• Prescription volume trend by quarter (seasonality-adjusted)
• Retail fill share and reimbursement dynamics
• Post-generic entry volume migration where relevant

What FDA regulatory factors affect Natroba’s market access and competitor timing?

A full FDA access timeline requires:

• NDA/BLA identifiers
• Approved formulation and labeling changes
• Any safety communications impacting usage
• The approval status of competitor ANDAs (if any) and related patent certifications

No regulatory dataset was included.

What manufacturing and supply-chain/IP barriers influence Natroba’s ability to defend share?

For a topical suspension, supply-chain defense can depend on:

• Suspension stability and batch consistency
• Container-closure compatibility
• Scale-up and fill-finish capacity
• Patents tied to manufacturing processes

A barrier analysis requires knowledge of the manufacturing patents and any history of supply constraints, which were not provided.

What commercial strategy moves most affect Natroba’s revenue trajectory?

In head lice, the commercial levers that typically move net revenue are:

• Contracting posture with PBMs (rebate level and formulary placement).
• Bulk purchasing and school or community channel partnerships (if used in a given period).
• Patient assistance programs that reduce copays and improve adherence to regimen instructions.
• Medical-education and HCP targeting that affects prescriber switching.

A specific view for Natroba requires evidence of those actions across time, which is not included.

Key Takeaways

• Natroba’s market dynamics are dominated by acute head-lice episode demand, payer formulary rules, and substitution versus OTC and competing prescription pediculicides.
• A credible financial trajectory requires net sales, prescription volume, and gross-to-net data; none were provided, so numeric trends and revenue CAGR cannot be stated.
• Exclusivity loss, Orange Book patent counts, and generic entry risks require Orange Book listings and patent litigation records; these were not included, so specific expiration and entry timing cannot be reported.
• Competitive pressure in this category is likely to increase as alternative products maintain formulary access at lower net prices.

FAQs

1. How does Natroba compare to permethrin-based lice treatments on prescription persistence and re-treatment rates?
2. What payer criteria commonly drive prior authorization for spinosad topical suspension 0.9%?
3. What generic or authorized-competitor entry scenarios are most likely for a topical suspension product like Natroba?
4. How do wholesalers’ sell-in cycles and seasonality in head lice outbreaks affect quarterly Natroba performance?
5. Which patent categories most often block generics for topical dermatology suspensions even after core drug-substance patents expire?

References

1. (No sources were provided or retrievable in the prompt context.)

DrugChatter Q&A for NATROBA

Natroba 0.9 topical suspension?